Emcure Pharmaceuticals announced the commercial launch of Poviztra, a semaglutide injection for chronic weight management, marking its entry into India’s fast-growing obesity and metabolic health segment.
Product and pricing
In an exchange filing, the Pune-based drugmaker said it is the first Indian company to exclusively distribute and commercialise Poviztra, positioned as a second brand of Novo Nordisk’s semaglutide for weight management. The drug will be sold across India in a once-weekly pen device and will be available in five dosage strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg.
Prices will start at Rs 8,790 per month, covering four weekly doses, the company said.
Semaglutide is prescribed as an adjunct to a reduced-calorie diet and increased physical activity for adults with obesity, or overweight individuals with at least one related condition such as type 2 diabetes, hypertension or dyslipidaemia. The formulation is also approved to reduce the risk of major adverse cardiovascular events in certain high-risk patients.
Citing the scale of India’s obesity burden, Emcure’s chief executive and managing director Satish Mehta said the country has nearly 254 million people living with generalised obesity and another 351 million with abdominal obesity. “The introduction of Poviztra marks an important step in expanding equitable access to scientifically validated weight-management solutions,” he said.
The company said the launch is backed by extensive global clinical data on semaglutide, including late-stage trials that have demonstrated significant weight reduction. The molecule has been in global use for nearly a decade.
About Emcure Pharmaceuticals
The move comes as Indian pharmaceutical companies increasingly expand into lifestyle and chronic therapies amid rising demand for treatments targeting obesity and metabolic disorders.
Emcure, which operates in over 70 countries, reported a 25.1% year-on-year rise in consolidated net profit to Rs 243 crore for the September quarter, while revenue from operations grew 13.4% to Rs 2,269.8 crore. EBITDA rose 25% to Rs 475.4 crore, with margins improving to 21%, aided by a better product mix and cost efficiencies.
Shares of Emcure Pharmaceuticals closed at Rs 1,385.10 per share as of 22 December closing. The share price rose 1.55% in the past month and rose 4.96% in the past three months.